Literature DB >> 2720709

Preferential homing of tumor-infiltrating lymphocytes in tumor-bearing mice.

I H Ames1, G M Gagne, A M Garcia, P A John, G M Scatorchia, R H Tomar, J G McAfee.   

Abstract

In view of the current interest in the use of lymphoid cells in adoptive immunotherapy of patients with advanced cancer, we have studied the homing patterns of various lymphoid effector cells in mammary-tumor-bearing mice. Single-cell suspensions of total splenocytes, natural killer (NK) cells, and lymphokine-activated killer (LAK) cells were prepared from the spleens of C3H/OuJ mice. Tumor-infiltrating lymphocytes (TIL) were isolated from mammary adenocarcinomas excised from retired breeder females of the same substrain. Effector cells were labeled with indium-111 and injected via a tail vein into female C3H/OuJ mice bearing one or more mammary tumors. Twenty-four hours after administration, total splenocytes, NK cells, and LAK cells distributed themselves evenly between normal mammary tissue and mammary adenocarcinomas. Only TIL had a higher concentration in tumors than in corresponding normal mammary tissue. The ability of the different lymphocyte preparations to lyse YAC-1 cells was determined by means of a 4-h 51Cr-release cytotoxicity assay. Cells harvested from LAK cell cultures and further enriched by centrifugation through a discontinuous Percoll gradient and interleukin-2 (IL-2)-stimulated TIL demonstrated the highest levels of cytotoxicity, while total splenocytes and fresh TIL were characterized by the lowest levels. Since IL-2-stimulated TIL were highly cytotoxic and exhibited better tumor localization than both NK cells and LAK cells in this system, they may be the lymphoid effectors of choice for adoptive immunotherapy of advanced cancer.

Entities:  

Mesh:

Year:  1989        PMID: 2720709     DOI: 10.1007/BF00199283

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  48 in total

Review 1.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

Review 2.  Passive immunotherapy of cancer in animals and man.

Authors:  S A Rosenberg; W D Terry
Journal:  Adv Cancer Res       Date:  1977       Impact factor: 6.242

3.  Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

Authors:  R Lafreniere; S A Rosenberg
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

4.  Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer.

Authors:  R L Kradin; L A Boyle; F I Preffer; R J Callahan; M Barlai-Kovach; H W Strauss; S Dubinett; J T Kurnick
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

5.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

Authors:  J J Mulé; S Shu; S L Schwarz; S A Rosenberg
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728

6.  Immunohistological analysis of lymphocyte subpopulations infiltrating breast carcinomas and benign lesions.

Authors:  S von Kleist; J Berling; W Bohle; C Wittekind
Journal:  Int J Cancer       Date:  1987-07-15       Impact factor: 7.396

7.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Authors:  S L Topalian; D Solomon; F P Avis; A E Chang; D L Freerksen; W M Linehan; M T Lotze; C N Robertson; C A Seipp; P Simon
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

8.  Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

Authors:  A Belldegrun; L M Muul; S A Rosenberg
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

9.  In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.

Authors:  N Takai; R Tanaka; S Yoshida; N Hara; T Saito
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

10.  Generation of lymphokine-activated killer (LAK) cells from tumor-infiltrating lymphocytes.

Authors:  T Nishimura; H Yagi; Y Uchiyama; Y Hashimoto
Journal:  Cell Immunol       Date:  1986-06       Impact factor: 4.868

View more
  12 in total

1.  Confusion about the tissue distribution of lymphokine-activated killer (LAK) cells.

Authors:  A A Maghazachi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Tissue distribution of adoptively transferred adherent lymphokine-activated killer cells assessed by different cell labels.

Authors:  P Basse; R B Herberman; M Hokland; R H Goldfarb
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes.

Authors:  C D Rice; N G Baldwin; R T Biron; H D Bear; R E Merchant
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

4.  Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies.

Authors:  E W Nijhuis; E vd Wiel-van Kemenade; C G Figdor; R A van Lier
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes.

Authors:  D J Cole; J K Taubenberger; B A Pockaj; J R Yannelli; C Carter; J Carrasquillo; S Leitman; S M Steinberg; S A Rosenberg; Y C Yang
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

6.  Fate of intravenously administered rat lymphokine-activated killer cells labeled with different markers.

Authors:  A A Maghazachi; L Fitzgibbon
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 7.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

8.  In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.

Authors:  J S Economou; A S Belldegrun; J Glaspy; E M Toloza; R Figlin; J Hobbs; N Meldon; R Kaboo; C L Tso; A Miller; R Lau; W McBride; R C Moen
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

9.  Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.

Authors:  Joao Santos; Camilla Heiniö; Dafne Quixabeira; Sadia Zafar; James Clubb; Santeri Pakola; Victor Cervera-Carrascon; Riikka Havunen; Anna Kanerva; Akseli Hemminki
Journal:  Cells       Date:  2021-04-22       Impact factor: 6.600

10.  Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.

Authors:  Lili Song; Shikai Liu; Sufen Zhao
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.